Working… Menu

Treatment of Chronic Migraine Headaches. (Migraine)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03220113
Recruitment Status : Unknown
Verified July 2017 by Corona Doctors Medical Clinics, Inc..
Recruitment status was:  Recruiting
First Posted : July 18, 2017
Last Update Posted : April 4, 2018
Information provided by (Responsible Party):
Corona Doctors Medical Clinics, Inc.

Brief Summary:

The purpose of the study is assessment of the safety and efficacy of the De-Novo therapy in the treatment of craniofacial neuralgia and migraine headaches.This is an open-label study of simultaneous administration of combination of dexamethasone, lidocaine, and thiamine into the trigeminal nerve branches as well as greater and lesser occipital nerve bilaterally in one session.

Patients who meet the exclusion and inclusion criteria are eligible for trial if they have experienced chronic migraine and craniofacial pain not responding to other prior therapies.

Condition or disease Intervention/treatment Phase
Chronic Migraine Without Aura, Intractable Migraine With Typical Aura Migraine Disorders Combination Product: Dexamethasone, Lidocaine, Thiamine cohort Phase 1 Phase 2

Detailed Description:

A combination of dexamethasone, lidocaine and thiamine (pat.), may bring changes in the pattern of sympathetic and parasympathetic nerve signaling at the level vasa nervorum. These changes may down-regulate the hyperexcitable sympathetic signals at the level of adventitia and consequently the medial layer of vasa nervorum and providing long term relief from migraine headaches. However, a bilateral and simultaneous treatment of trigeminal and occipital nerves in migraine and craniofacial neuralgia using a combination of dexamethasone, thiamine and lidocaine has been rarely studied.

The objective of this study is to assess the safety and efficacy of concomitant administration of dexamethasone, lidocaine, and thiamine compounds into the trigeminal nerve branches, the greater and lesser occipital nerve for the treatment of chronic migraine, and craniofacial neuralgia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective Open Label Study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches.
Actual Study Start Date : July 1, 2017
Estimated Primary Completion Date : July 1, 2018
Estimated Study Completion Date : July 1, 2019

Arm Intervention/treatment
Experimental: Dexamethasone,Lidocaine,Thiamine cohort

Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.

De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles.

Combination Product: Dexamethasone, Lidocaine, Thiamine cohort
Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
Other Name: De-Novo Treatment Cohort medication

Primary Outcome Measures :
  1. Assessment of the safety to the De-Novo treatment formula in study patients [ Time Frame: 5 weeks ]
    Study assesses the safety of the De-Novo algorithm( if patients who receive this treatment will experience any major adverse reactions due to the medication combination )within the next 5 weeks following treatment. Participants will be interviewed after the initial treatment weekly, for 5 weeks to evaluate for any possible adverse events, hospitalization, or treatment. Any significant adverse event in over 45% of participants, may project end of the trial.

Secondary Outcome Measures :
  1. Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure [ Time Frame: 12 months ]

    Assessment of the clinical response to the De-Novo treatment formula in study patients.

    Study assesses the efficacy parameters of the study ( i.e. the change in baseline frequency of migraine attack in patients post initial treatment ), and functionality status based on continuation of work performance and return to work or school.

    Therefore, the Outcome of study consisting of multiple measures and present lone composite measure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • • Age: 10-90 years

    • Ability to describe headache and its symptoms
    • Ability to read, comprehend, and legibly and reliably record information
    • Ability to provide written, informed consent, and respond to pre and post treatment questionnaires, children's guardian accepts responsibility. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures
    • Already diagnosed with chronic craniofacial neuralgia and chronic migraine headache
    • Exhausted all or most of available abortive and preventive treatment modalities.

Exclusion Criteria:

  • • Uncontrollable hypertension, acute Myocardial Infarct within last 6 months

    • History of cerebral vascular aneurysm/known atherosclerosis of cerebral system, brain tumor
    • Implanted of neuro-stimulator, trigeminal tractotomy, neurectomy partial or complete, history of gamma knife treatment, microsurgical decompression procedure.
    • Hypersensitivity or allergy to any components of De-Novo formula
    • Presence or known anatomic craniofacial deformities or severe spondylosis/spondylolisthesis of cervical spine, profound dental caries, Maxillofacial deformities
    • Pregnancy and current breast feeding status
    • Headaches attribute to acute head and neck injuries, chronicity of cervicogenic headaches
    • Skin infection or micro abscesses dermatogen or dental, ongoing treatment for Methicillin Resistant Streptococcus Aureus ( MRSA) unless treatment completed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03220113

Layout table for location contacts
Contact: Faro T. Owiesy, M.D. 9513719500
Contact: Jovana Martin Murillo 9513719500

Layout table for location information
United States, California
Corona Doctors Medical Clinics Inc Recruiting
Corona, California, United States, 92879
Contact: Faro T Owiesy    951-371-9500   
Contact: Jovana Martin Murillo    9513719500   
Principal Investigator: Faro T Owiesy, MD         
Sponsors and Collaborators
Corona Doctors Medical Clinics, Inc.
Layout table for investigator information
Principal Investigator: Faro T. Owiesy, M.D. Corona Doctors Medical Clinics, Inc.

Layout table for additonal information
Responsible Party: Corona Doctors Medical Clinics, Inc. Identifier: NCT03220113    
Other Study ID Numbers: 2017/05/1
First Posted: July 18, 2017    Key Record Dates
Last Update Posted: April 4, 2018
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No sharing suggested at this time

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corona Doctors Medical Clinics, Inc.:
Craniofacial Neuralgia
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Migraine without Aura
Migraine with Aura
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anesthetics, Local
Central Nervous System Depressants
Sensory System Agents
Anti-Arrhythmia Agents